RxDoctor Payments Data

Lisa Cook, MD

Neurology · Los Angeles, CANPI 1508983222

Payments from drug & device makers

$271,088in general payments, 2019–2025

Across 1,539 payments — averaging $176.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$151K
  • Pfizer$35K
  • Impel Pharmaceuticals Inc.$20K
  • Merz Pharmaceuticals, LLC$18K
  • Biohaven Pharmaceutical Holding Company Ltd.$15K
  • Biohaven Pharmaceuticals, Inc.$12K
  • plus $19K from 54 others
$48,825in research payments, 2019–2025

Across 37 payments — averaging $1319.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ipsen Innovation$48K
  • Avanir Pharmaceuticals, Inc.$490

What the payments were for

  • Consulting fees$39,54616%
  • Speaking & faculty fees$169,84467%
  • Travel & lodging$9,9684%
  • Food & beverage$34,56914%
  • Education$1610%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)544$151,362
Pfizer88$35,253
Impel Pharmaceuticals Inc.35$20,316
Merz Pharmaceuticals, LLC28$17,878
Biohaven Pharmaceutical Holding Company Ltd.54$14,560
Biohaven Pharmaceuticals, Inc.41$12,467
Upsher-smith Laboratories LLC140$3,837
Teva Pharmaceuticals USA, Inc.120$3,283
Lilly USA, LLC83$1,858
Lundbeck LLC70$1,776
Amgen39$838
Biogen31$722
Tonix Medicines, Inc.6$615
Sanofi23$588
Axsome Therapeutics, Inc.14$565
Eisai Inc.15$476
CSL Behring16$422
Merz North America, Inc.14$333
EMD Serono, Inc.14$310
Genentech USA, Inc.8$253
Takeda Pharmaceuticals U.S.A., Inc.11$234
Acadia Pharmaceuticals Inc11$232
Scilex Pharmaceuticals Inc.12$221
Zyla Life Sciences, Inc.17$205
Jazz Pharmaceuticals Inc.7$188
Supernus Pharmaceuticals, Inc.11$160
SK Life Science, Inc.6$160
Tanabe Pharma America, Inc.5$117
AstraZeneca(2 entities)5$111
Neurelis, Inc.5$110
Avanir Pharmaceuticals, Inc.5$108
Neurocrine Biosciences, Inc.1$107
Stryker1$106
Alnylam Pharmaceuticals Inc.4$89
Amneal Pharmaceuticals LLC4$88
Argenx US, Inc.3$82
Otsuka America Pharmaceutical, Inc.4$81
Forte Bio-pharma LLC3$76
Bausch Health US, LLC4$70
Novartis3$68
UCB, Inc.3$62
Vertex2$58
Promius Pharma LLC3$57
Mallinckrodt Hospital Products Inc.2$56
Genentech, Inc.2$47
Harmony Biosciences LLC1$44
Assertio Therapeutics, Inc.4$42
Revance Therapeutics, Inc.1$36
Irhythm Technologies, Inc.1$36
Sunovion Pharmaceuticals Inc.1$29
Johnson & Johnson1$27
Life Molecular Imaging Ltd1$26
GE HealthCare1$26
Collegium Pharmaceutical, Inc.1$25
OWP Pharmaceuticals, Inc.1$24
Octapharma USA, Inc.1$24
Avadel CNS Pharmaceuticals, LLC1$23
Tersera Therapeutics LLC1$22
Impel Pharmaceuticals LLC1$22
Ipsen Biopharmaceuticals, Inc1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$271,088 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$571,246
Medicare patients
418
Services billed
66,572

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5012$154,849
Nurtec OdtRimegepant Sulfate36$62,322
QuliptaAtogepant38$56,936
UbrelvyUbrogepant46$53,375
NuedextaDextromethorphan Hbr/Quinidine16$24,420
Emgality PenGalcanezumab-Gnlm27$19,374
Memantine Hcl87$3,737
Sumatriptan Succinate43$2,425
Olanzapine OdtOlanzapine13$1,438
Pregabalin32$1,092
Primidone31$1,046
Donepezil Hcl78$868
Levetiracetam15$797
Gabapentin67$724
Nortriptyline Hcl19$564

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Nurtec Odt$35,253$217,17148 claims
AbbVieQulipta, Ubrelvy$151,362$110,31184 claims
Avanir Pharmaceuticals, Inc.Nuedexta$108$24,42016 claims
Upsher-smith Laboratories LLCTopiramate$3,837$12812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,996 neurology providers in California.

Other neurology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →